Regeneron Pharmaceuticals, Inc.

The Royal Institution for the Advancement of Learning/mcgill University

Luca Andrea Lotta

Aris I Baras

Olukayode Sosina

Manuel Allen Revez Ferreira

Parsa Akbari

Niek Verweij

Adam Locke

Mary Haas

John Brent Richards

Jonas Nielsen

Jonas Bovijn

Sirui Zhou

Charles Paulding

Garen Manvelian

Julie Horowitz

Amy Damask

Colm O'Dushlaine

Michael Cantor

Jonathan Marchini

The present disclosure provides methods of treating subjects having sepsis, SIRS, septic shock, and/or MODS, methods of identifying subjects having an increased risk of developing sepsis, SIRS, septic shock, and/or MODS, and methods of detecting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and/or Low Density Lipoprotein Receptor (LDLR) variant nucleic acid molecules and variant polypeptides.

Treatment of sepsis with PCSK9 and LDLR modulators

The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.

Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors

The present disclosure provides methods of treating subjects having liver disease, and methods of identifying subjects having an increased risk of developing liver disease.

Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors

The present disclosure provides methods of treating a subject having a liver disease or type 2 diabetes, and methods of identifying subjects having an increased risk of developing a liver disease or type 2 diabetes.

Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

Methods of treating obesity and methods of identifying susceptibility of an obese subject to treatment with an agonist of the leptin-melanocortin signaling pathway are provided herein.

Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof

The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.

Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.

Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors

The present disclosure provides methods of treating subjects having obesity and/or increased body mass index (BMI), and methods of identifying subjects having an increased risk of developing obesity and/or BMI.

Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)

Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors

The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.

Growing community of inventors

Tarrytown, NY, United States of America

Luca Andrea Lotta